Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XAVSH
ADC Name
F131-LD038
Synonyms
F131 LD038
   Click to Show/Hide
Organization
ProfoundBio (Suzhou) Co., Ltd.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Gestational choriocarcinoma [ICD11:2C75]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
8
Antibody Name
F131
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
F131-LD038 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 64.5
%
OV-90 cells
Ovarian adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 72.2
%
NCI-H292 cells
Lung mucoepidermoid carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
29.1
nM
JEG-3 cells
Gestational choriocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
62.4
nM
OVCAR-3 cells
Ovarian serous adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
173.5
nM
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 64.5% (Day 18) Positive FOLR1 expression (FOLR1+++/++)
Method Description
To establish ovarian cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 5 mg/kg.
In Vivo Model OV-90 CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 72.20% (Day 19) Positive FOLR1 expression (FOLR1+++/++)
Method Description
To establish lung cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 5 mg/kg.
In Vivo Model NCI-H292 CDX model
In Vitro Model Lung mucoepidermoid carcinoma NCI-H292 cells CVCL_0455
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 21) Positive FOLR1 expression (FOLR1+++/++)
Method Description
To establish oral epidermal cancer model, 5 x 106 cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm3 mice were randomly allocated to treatment groups. The dose of ADC was 5 mg/kg.
In Vivo Model KB CDX model
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 29.10 nM Positive FOLR1 expression (FOLR1+++/++)
Method Description
Potency of compounds and ADCs was evaluated using the JEG-3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model Gestational choriocarcinoma JEG-3 cells CVCL_0363
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 62.40 nM Positive FOLR1 expression (FOLR1+++/++)
Method Description
Potency of compounds and ADCs was evaluated using the OVCAR3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model Ovarian serous adenocarcinoma OVCAR-3 cells CVCL_0465
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 173.50 nM Positive FOLR1 expression (FOLR1+++/++)
Method Description
Potency of compounds and ADCs was evaluated using the KB cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
References
Ref 1 Linkers, drug linkers and conjugates thereof and methods of using the same; 2023-02-16.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.